Petr Szturz1,2, Pol Specenier3,4, Carl Van Laer4,5, Danielle Van Den Weyngaert4,6, Bob Corthouts7, Laurens Carp8, Eric Van Marck9, Olivier Vanderveken4,5, Jan B Vermorken3,4. 1. Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium. petr.szturz@fnbrno.cz. 2. Department of Internal Medicine, Hematology and Oncology, School of Medicine, University Hospital Brno and Masaryk University, Brno, Czech Republic. petr.szturz@fnbrno.cz. 3. Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium. 4. Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. 5. Department of Otorhinolaryngology and Head and Neck Surgery, Antwerp University Hospital, Edegem, Belgium. 6. Department of Radiotherapy, University Radiotherapy Antwerp, Antwerp, Belgium. 7. Department of Radiology, Antwerp University Hospital, Edegem, Belgium. 8. Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium. 9. Department of Pathology, Antwerp University Hospital, Edegem, Belgium.
Abstract
BACKGROUND: In recurrent head and neck squamous cell carcinoma ineligible for resection or irradiation, treatment aims primarily at symptom control and quality of life enhancement with an expected outcome of 6-12 months. METHODS:In 2005, a male patient, born in 1944, with a second local recurrence of human papillomavirus negative tonsil cancer was enrolled in the EXTREME trial, and randomized to platinum/5-fluorouracil/cetuximab arm resulting in partial remission with progression-free survival of 12 months. The second-line systemic therapy comprised 5 cycles of 3-weekly docetaxel/cisplatin/5-fluorouracil regimen plus weekly cetuximab. RESULTS: As confirmed on imaging and repeated biopsies, complete response was achieved with disease-free survival of 8 years and follow-up period of 12 years. Severe acute toxicities during the taxane-based chemotherapy plus cetuximab included grade 4 anorexia and grade 3 febrile neutropenia. CONCLUSIONS:Poor tumor differentiation, no weight loss, oropharyngeal location, white race, and particularly the induced complete response were most likely the key favorable prognostic factors in the reported patient. The possibility of a synergistic interaction between taxanes and cetuximab should be further explored.
RCT Entities:
BACKGROUND: In recurrent head and neck squamous cell carcinoma ineligible for resection or irradiation, treatment aims primarily at symptom control and quality of life enhancement with an expected outcome of 6-12 months. METHODS: In 2005, a male patient, born in 1944, with a second local recurrence of human papillomavirus negative tonsil cancer was enrolled in the EXTREME trial, and randomized to platinum/5-fluorouracil/cetuximab arm resulting in partial remission with progression-free survival of 12 months. The second-line systemic therapy comprised 5 cycles of 3-weekly docetaxel/cisplatin/5-fluorouracil regimen plus weekly cetuximab. RESULTS: As confirmed on imaging and repeated biopsies, complete response was achieved with disease-free survival of 8 years and follow-up period of 12 years. Severe acute toxicities during the taxane-based chemotherapy plus cetuximab included grade 4 anorexia and grade 3 febrile neutropenia. CONCLUSIONS: Poor tumor differentiation, no weight loss, oropharyngeal location, white race, and particularly the induced complete response were most likely the key favorable prognostic factors in the reported patient. The possibility of a synergistic interaction between taxanes and cetuximab should be further explored.
Authors: Yong Park; Dae S Kim; Kyong H Park; Seung-Kuk Baek; Soon Y Kwon; Sang W Shin; Kwang Y Jung; Chul Y Kim; Yeol H Kim; Nam J Lee; Jun S Kim; In S Kim Journal: Onkologie Date: 2012-10-22
Authors: A A Forastiere; B Metch; D E Schuller; J F Ensley; L F Hutchins; P Triozzi; J A Kish; S McClure; E VonFeldt; S K Williamson Journal: J Clin Oncol Date: 1992-08 Impact factor: 44.544
Authors: John C Sok; Francesca M Coppelli; Sufi M Thomas; Miriam N Lango; Sichuan Xi; Jennifer L Hunt; Maria L Freilino; Michael W Graner; Carol J Wikstrand; Darell D Bigner; William E Gooding; Frank B Furnari; Jennifer R Grandis Journal: Clin Cancer Res Date: 2006-09-01 Impact factor: 12.531
Authors: J Santini; J L Formento; M Francoual; G Milano; M Schneider; O Dassonville; F Demard Journal: Head Neck Date: 1991 Mar-Apr Impact factor: 3.147
Authors: D M Shin; F R Khuri; B S Glisson; L Ginsberg; V M Papadimitrakopoulou; G Clayman; J J Lee; K K Ang; S M Lippman; W K Hong Journal: Cancer Date: 2001-04-01 Impact factor: 6.860
Authors: R P Morton; F Rugman; E B Dorman; P J Stoney; J A Wilson; M McCormick; A Veevers; P M Stell Journal: Cancer Chemother Pharmacol Date: 1985 Impact factor: 3.333
Authors: Ambika Parmar; Michaelina Macluskey; Niall Mc Goldrick; David I Conway; Anne-Marie Glenny; Janet E Clarkson; Helen V Worthington; Kelvin Kw Chan Journal: Cochrane Database Syst Rev Date: 2021-12-20